# 2025-08145: Bug DNA Storage Gadget Gets FDA Classification

2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Microbial Nucleic Acid Storage and Stabilization Device, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08145
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08145
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Microbial Nucleic Acid Storage and Stabilization Device
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19644
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

Bug DNA Storage Gadget Gets FDA Classification

## Summary

The FDA is officially putting microbial nucleic acid storage and stabilization devices into class II, meaning they’ll have special safety rules but less red tape. This change helps companies bring these devices to market faster while keeping patients safe. It affects manufacturers and healthcare providers starting May 9, 2025, and aims to boost innovation without extra costs.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the microbial nucleic acid storage and stabilization device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the microbial nucleic acid storage and stabilization device's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device moved to Class II (special controls): benefit, medium. The FDA has officially classified microbial nucleic acid storage and stabilization devices as Class II (special controls). The final order is effective May 9, 2025 (the classification was applicable March 19, 2018). FDA says this change will reduce regulatory burdens and help patients get innovativ…
- Device subject to 510(k) premarket notification: benefit, medium. Under this classification, the device is subject to premarket notification under section 510(k) of the FD&C Act rather than automatic Class III premarket approval. This allows sponsors to use the 510(k) pathway and, when applicable, for this device to serve as a predicate for future 510(k) submissi…
- New labeling and validation requirements for makers: cost, medium. Manufacturers must meet specific special controls in 21 CFR 866.2950, including labeling that lists microorganisms and specimen types, a detailed device description, performance data including nucleic acid stability and microorganism inactivation, limiting statements about compatibility and validat…
- Special controls address false negatives and inactivation risks: benefit, medium. FDA identified risks to health such as false negative results from failure to stabilize nucleic acid and risks from failure to inactivate specimens. FDA states that the general controls plus the named special controls will mitigate these risks and provide reasonable assurance of safety and effectiv…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08145 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08145/medical-devices-immunology-and-microbiology-devices-classification-of-the-microbial-nucleic-acid)
- [2025-08145 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08145.pdf)

## Related
- [Previous: 2025-08144, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2025-08144)
- [Next: 2025-08146, Medical Devices; Immunology and Microbiology Devices; Classification of the Cyt…](https://policyrisk.com/federal-register/2025-08146)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08145 (as of 2026-10-16).
